Panelists:
Brian O’Mara
VP of Process Sciences
Scorpius BioManufacturing
Angela Lewandowski, PhD
Senior Director, Downstream Bioprocess Development
Bristol Myers Squibb
Buzz Lobbezoo
Senior Field Application Specialist
Thermo Fisher Scientific
- Time:
The landscape of novel monoclonal antibody (mAb) therapeutic formats has expanded significantly in recent years, introducing new challenges in the purification process. Traditional full-length IgG molecules are now supplemented by antigen-binding fragments, bispecific antibodies, and antibody-drug conjugates, each with unique physicochemical properties and structural differences. These diverse formats require tailored purification strategies due to variations in their fundamental structure and modified physical properties such as size, charge, and hydrophobicity. Addressing this challenge requires specific chromatography approaches, including modified chromatographic techniques such as novel affinity techniques and multimodal chromatography or mixed-mode resins, which can effectively capture and polish diverse mAb formats.
In this GEN webinar, our expert panelists will discuss key challenges in the purification process of complex mAbs and suggest strategies for mitigating their effects. Among the topics covered will be:
- Issues with affinity capture, which is critical for identifying appropriate ligands for various mAb formats.
- Problems with polishing, which is required to remove impurities without affecting the structural integrity of mAbs.
- Considerations for choosing resins for unit operations as well as building effective downstream processing systems and protocols for mAb purification.
A live Q&A session will follow the presentation, offering you a chance to pose questions to our expert panelists.
Produced with support from:
